Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2008 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: May 9, 2009
Last updated: August 9, 2013
Last verified: April 2008

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help the study of cancer in the future.

PURPOSE: This laboratory study is looking at tumor tissue samples from patients with melanoma who have undergone sentinel lymph node biopsy.

Condition Intervention
Melanoma (Skin)
Genetic: gene expression analysis
Genetic: mutation analysis
Other: diagnostic laboratory biomarker analysis
Other: immunohistochemistry staining method
Procedure: sentinel lymph node biopsy

Study Type: Observational
Official Title: A Retrospective Case-Control Study of Melanoma Patients Who Have Undergone Sentinel Lymph Node Biopsy

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Predictive model for sentinel lymph node biopsy positivity
  • Survival model for relapse
  • Genetic determinants in primary melanomas that predict a metastatic phenotype

Estimated Enrollment: 1000
Study Start Date: January 2007
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Detailed Description:


  • Develop a predictive model for sentinel lymph node biopsy positivity in patients with melanoma who have undergone sentinel lymph node biopsy.
  • Develop a survival model for relapse based on sentinel lymph node biopsy positivity.
  • Assess the genetic determinants in primary melanomas that predict a metastatic phenotype and thereby improve understanding of the biology of the metastases in melanoma.

OUTLINE: This is a retrospective, case-controlled, multicenter study. Patients are stratified according to Breslow thickness of the tumor (0.75-1.50 mm vs 1.51- 4 mm vs > 4 mm) and gender.

Archived tumor tissue is analyzed by immunohistochemistry (IHC) for AP2, vascular endothelial growth factor, MMP 2, MCM4, and others, if feasible. Sentinel node biopsies are analyzed by IHC for CD31, LYVE-1, and D2-40 expression. RNA and DNA are also extracted for genetic expression studies and mutation analysis (e.g., BRAF, NRAS, PTEN, CDKN2A).

Patient data related to relapse and recurrence is collected, if available.

Peer reviewed and funded or endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Confirmed diagnosis of cutaneous melanoma

    • Breslow thickness > 0.75 mm
  • Has undergone sentinel lymph node biopsy
  • No primary melanoma that has not originated in the skin
  • No multiple primary melanomas
  • Currently under clinical followup OR discharged from follow up within the past 3 months


  • No other malignancy except for nonmelanoma skin cancer or cervical carcinoma in situ


  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00897481

United Kingdom
Leeds Cancer Centre at St. James's University Hospital Recruiting
Leeds, England, United Kingdom, LS9 7TF
Contact: Julia Newton Bishop, MD    44-113-206-4668      
Sponsors and Collaborators
Leeds Cancer Centre at St. James's University Hospital
Study Chair: Julia Newton Bishop, MD Leeds Cancer Centre at St. James's University Hospital
  More Information Identifier: NCT00897481     History of Changes
Other Study ID Numbers: CRUK-LCC-06/Q1206/149
CDR0000532943 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: May 9, 2009
Last Updated: August 9, 2013

Keywords provided by National Cancer Institute (NCI):
stage IV melanoma
recurrent melanoma
stage IA melanoma
stage IB melanoma
stage IIA melanoma
stage IIB melanoma
stage IIC melanoma
stage IIIA melanoma
stage IIIB melanoma
stage IIIC melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on May 25, 2017